Search Results

In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.

Heartseed Inc., a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc., a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed’s proprietary cardiomyocytes differentiation and purification methods.

PRNewswire -- I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing

I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette.

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.